2016 O. M. Ivanova*, R. H. Ziganshin*, #, G. P. Arapidi*, **, S. I. Kovalchuk*, I. V. Azarkin*, A. V. Sorokina***, V. M. Govorun*, ****, V. E. Radzinsky***, and V. T. Ivanov*

#Phone: +7 (495) 336-07-77; e-mail:

*Department of Proteomics, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, ul. Miklukho-Maklaya, 16/10, GSP-7, Moscow, 117997 Russia;
**Faculty of Molecular and Biological Physics, Moscow Institute of Physics and Technology, Institutskii pereulok, 9, Dolgoprudny, Moscow region, 141700 Russia;
***Department of Obstetrics and Gynecology with the course of Perinatology, Medical faculty, Peoples Friendship University of Russia, ul. Miklukho-Maklaya, 8, Moscow, 117198 Russia;
****Institute of Physical-Chemical Medicine, Federal Agency for Health Care and Social Development, ul. Malaya Pirogovskaya, 1a, Moscow, 119992 Russia

Received January 22, 2016; in final form, April 25, 2016

DOI: 10.7868/S0132342316050079

Serum samples (33 healthy women, 34 ovarian cancer, 28 colorectal cancer, 34 syphilis patients and 136 patients with various benign gynecological diseases) were analyzed by MALDI-TOF MS peptide profiling and respective predictive models were generated by genetic and supervised neural network algorithms. Classification models for pathology versus healthy control showed up to 100% sensitivity and specificity for all target diseases. However, the specificity dropped to unsatisfactory 2540% in case of target versus non-target disease diagnostics. Expansion of the control group to an artificial nominal control group by adding profiles of benign gynecological diseases considerably improved specificity of the models distinguishing ovarian cancer from healthy control and benign gynecological diseases. The suggested version of MALDI-TOF MS profiling of sera could be applied to differentiate between cancers and benign neoplasms of the same localization which is a challenging task for classical methods. To increase the specificity of diagnostic methods based on peptidome analysis of blood samples, it is necessary to identify sets of concrete peptide structures which qualitatively or quantitatively differ among patients with different diseases.

Keywords: MALDI-TOF MS peptide profiling, serum, ovarian cancer, colorectal cancer, benign gynecological diseases, diagnostics.

. 2016, 42 (5): 552-560